公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2010 | Effect of nateglinide on the incidence of diabetes and cardiovascular events | Holman R.R.; Haffner S.M.; McMurray J.J.; Bethel M.A.; Holzhauer B.; Hua T.A.; Belenkov Y.; Boolell M.; Buse J.B.; Buckley B.M.; Chacra A.R.; FU-TIEN CHIANG ; Charbonnel B.; Chow C.-C.; Davies M.J.; Deedwania P.; Diem P.; Einhorn D.; Fonseca V.; Fulcher G.R.; Gaciong Z.; Gaztambide S.; Giles T.; Horton E.; Ilkova H.; Jenssen T.; Kahn S.E.; Krum H.; Laakso M.; Leiter L.A.; Levitt N.S.; Mareev V.; Martinez F.; Masson C.; Mazzone T.; Meaney E.; Nesto R.; Pan C.; Prager R.; Raptis S.A.; Rutten G.E.H.M.; Sandstroem H.; Schaper F.; Scheen A.; Schmitz O.; Sinay I.; Soska V.; Stender S.; Tam?s G.; Tognoni G.; Tuomilehto J.; Villamil A.S.; Voz?r J.; Califf R.M. | New England Journal of Medicine | 449 | 332 | |
2018 | Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) | Davis T.M.E.; Mulder H.; Lokhnygina Y.; Aschner P.; LEE-MING CHUANG ; Raffo Grado C.A.; Standl E.; Peterson E.D.; Holman R.R.; for the TECOS Study Group | Diabetes, Obesity and Metabolism | 22 | 21 | |
2016 | Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS | Cornel J.H.; Bakris G.L.; Stevens S.R.; Alvarsson M.; Bax W.A.; LEE-MING CHUANG ; Engel S.S.; Lopes R.D.; McGuire D.K.; Riefflin A.; Rodbard H.W.; Sinay I.; Tankova T.; Wainstein J.; Peterson E.D.; Holman R.R. | Diabetes Care | 138 | 121 | |
2010 | Effect of valsartan on the incidence of diabetes and cardiovascular events | Califf R.M.; McMurray J.J.; Holman R.R.; Haffner S.M.; Bethel M.A.; Holzhauer B.; Hua T.A.; Belenkov Y.; Boolell M.; Buse J.B.; Buckley B.M.; Chacra A.R.; FU-TIEN CHIANG ; Charbonnel B.; Chow C.-C.; Davies M.J.; Deedwania P.; Diem P.; Einhorn D.; Fonseca V.; Fulcher G.R.; Gaciong Z.; Gaztambide S.; Giles T.; Horton E.; Ilkova H.; Jenssen T.; Kahn S.E.; Krum H.; Laakso M.; Leiter L.A.; Levitt N.S.; Mareev V.; Martinez F.; Masson C.; Mazzone T.; Meaney E.; Nesto R.; Pan C.; Prager R.; Raptis S.A.; Rutten G.E.H.M.; Sandstroem H.; Schaper F.; Scheen A.; Schmitz O.; Sinay I.; Soska V.; Stender S.; Tam?s G.; Tognoni G.; Tuomilehto J.; Villamil A.S.; Voz?r J. | New England Journal of Medicine | 539 | 502 | |
2012 | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: An observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial | Preiss D.; Thomas L.E.; Sun J.-L.; Haffner S.M.; Holman R.R.; Standl E.; Leiter L.A.; Mazzone T.; Rutten G.E.; Tognoni G.; Martinez F.A.; FU-TIEN CHIANG ; Califf R.M.; McMurray J.J. | BMJ Open | 22 | 20 | |
2013 | Predictors of stroke in patients with impaired glucose tolerance: Results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial | Preiss D.; Giles T.D.; Thomas L.E.; Sun J.-L.; Haffner S.M.; Holman R.R.; Standl E.; Mazzone T.; Rutten G.E.; Tognoni G.; FU-TIEN CHIANG ; McMurray J.J.V.; Califf R.M. | Stroke | 8 | 7 |